BioMed Research International

Advances in the Development of Biotherapeutics


Status
Published

1Institut Pasteur, Paris, France

2University of Natural Resources and Life Sciences (BOKU), Vienna, Austria

3Universidade Nova de Lisboa, Lisbon, Portugal

4Universidad Autónoma Metropolitana-Cuajimalpa, Mexico City, Mexico

5Imperial College London, London, UK


Advances in the Development of Biotherapeutics

Description

Biotherapeutics are currently the fastest growing group of pharmaceuticals, being a treatment option for a variety of chronic and sometimes life-threatening conditions. They represent a diverse group of biological products that broadly encompasses nucleic acids, proteins, whole cells, viral particles, and vaccines. In the recent years, great strides have been made toward the development of safer and more effective biotherapeutics, as well as in the adoption of cost-effective, more efficient, and streamlined manufacturing processes. This trend is expected to accelerate in the forthcoming years, as emerging fields related to advanced therapies or personalized medicine mature. Despite these progresses, there are still knowledge gaps across all stages of development, as well as technical and regulatory hurdles that can thwart the approval process of these products.

This special issue invites original research and review articles reporting on the recent developments and application of biotherapeutics.

Potential topics include, but are not limited to:

  • Nucleic-acid therapeutics (e.g., plasmid DNA, antisense technology, aptamers, siRNAs/miRNAs, CRISPRs)
  • Protein-based therapeutics (e.g., antibodies, cytokines, interferons, growth hormones, enzymes)
  • Vaccine technologies (vaccines, vectors, adjuvants)
  • Vector design and gene delivery
  • Advanced-cell therapeutics (e.g., primary cells, adult stem cells, embryonic stem cells, induced pluripotent stem cells)
  • Cell engineering to improve biomanufacturability
  • Biomanufacturing, up-/downstream processing and storage
  • Process analytical technology (PAT) and Quality by Design (QbyD)
  • Quality control and safety issues
  • Regulatory compliance and intellectual property
  • Biosimilars
  • Clinical testing

Articles

  • Special Issue
  • - Volume 2015
  • - Article ID 793876
  • - Editorial

Advances in the Development of Biotherapeutics

Pedro H. Oliveira | Juergen Mairhofer | ... | Cleo Kontoravdi
  • Special Issue
  • - Volume 2015
  • - Article ID 594120
  • - Research Article

Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter

F. C. Mariz | E. C. Coimbra | ... | A. C. Freitas
  • Special Issue
  • - Volume 2015
  • - Article ID 932161
  • - Review Article

Gene Delivery into Plant Cells for Recombinant Protein Production

Qiang Chen | Huafang Lai
  • Special Issue
  • - Volume 2015
  • - Article ID 427235
  • - Research Article

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab

Carlos A. López-Morales | Mariana P. Miranda-Hernández | ... | Emilio Medina-Rivero
  • Special Issue
  • - Volume 2015
  • - Article ID 605427
  • - Review Article

Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

Jesús Zurdo | Andreas Arnell | ... | Ingmarie Höidén-Guthenberg
  • Special Issue
  • - Volume 2015
  • - Article ID 592915
  • - Review Article

Diabetes and Stem Cell Function

Shin Fujimaki | Tamami Wakabayashi | ... | Tomoko Kuwabara
  • Special Issue
  • - Volume 2015
  • - Article ID 698067
  • - Research Article

The J-Domain of Heat Shock Protein 40 Can Enhance the Transduction Efficiency of Arginine-Rich Cell-Penetrating Peptides

Tzu-Yin Lin | Yu-Hsiu Su | ... | Chin-Kai Chuang
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit